One Day MD | Evidence-Based Wellness

Scientific Review & Regulatory Audit by the Clinical Editorial Team The therapeutic paradigm for progressive neurodegenerative disorders like Parkinson’s disease (PD) and various forms of dementia faces a critical bottleneck. Standard pharmacology, primarily anchored by levodopa (L-DOPA) for Parkinson’s and acetylcholinesterase inhibitors for dementia, remains strictly symptomatic. These options frequently suffer from diminishing efficacy and significant side-effect profiles like L-DOPA-induced dyskinesia over long-term use. Consequently, the pharmaceutical community has focused heavily on drug repurposing—identifying established, safety-vetted compounds capable of crossing pathways to modify disease progression. An unexpected frontline candidate emerging in this space is ivermectin. Traditionally classified as a broad-spectrum antiparasitic agent, a surge of preclinical studies between 2020 and 2024 has unveiled its complex, multi-targeted pharmacodynamics within the mam...

Glutathione deficiency is one of the most consistent and earliest biochemical abnormalities found in Parkinson’s disease and Alzheimer’s disease. Long before neurons are lost, the brain’s primary intracellular antioxidant is already depleted—leaving neurons vulnerable to oxidative stress, mitochondrial failure, and inflammation. This pillar page serves as a comprehensive, evidence-based hub explaining glutathione’s role in brain health, why it declines in neurodegenerative disease, and how it fits into modern systems medicine and metabolic models of neurodegeneration. Table of Contents What Is Glutathione? Why the Brain Depends on Glutathione Oxidative Stress and Neurodegeneration Glutathione in Parkinson’s Disease Glutathione in Alzheimer’s Disease Cause or Consequence? Why Glutathione Declines With Age Glutathione, Mitochondria & Metabolic Health Can Glutathione Be Restored? Biomarker & Clinical Implications Systems Medicine Perspective Key Takeaways What Is Glutathione? Glu...

The supplements with the strongest evidence for reducing Parkinson’s disease (PD) symptoms, based on current research and clinical studies, include: N-acetyl cysteine (NAC) and Glutathione :  Glutathione deficiency is an early event in PD progression. NAC helps increase glutathione levels, acting as a potent antioxidant. Small clinical trials suggest NAC may improve motor and cognitive symptoms by enhancing dopamine transporter function 1 . Mucuna pruriens :  This natural source of levodopa has demonstrated efficacy in managing motor symptoms of PD and may reduce side effects like dyskinesia when used under medical supervision. A double-blind controlled study supports its benefit in symptom control 6 . Coenzyme Q10 (CoQ10) :  An antioxidant involved in cellular energy production, CoQ10 may help improve neuronal function and protect against oxidative damage. However, clinical trials have not conclusively supported its routine use for PD symptom relief 2 6 . Vitamin C and V...